Osteopathic Manipulative Medicine to Reduce Developmental Delays

August 11, 2023 updated by: Ronnie Guillet, University of Rochester

Using Osteopathic Manipulative Medicine on Preterm Infants in the Neonatal Intensive Care Unit to Reduce Neuromotor Developmental Delays

This randomized clinical trial seeks to determine if osteopathic manipulative medicine (OMM) increases the likelihood of improved neurodevelopmental outcomes as estimated by the Test of Infant Motor Performance (TIMP).

Study Overview

Detailed Description

Hypothesis: High risk preterm infants born <34 weeks of gestation who receive OMM, compared to the standard supportive care, will have improved neuromotor development scores on the TIMP.

Specific Aims and Objectives:

Primary aim: To determine the difference in TIMP scores between infants who receive OMM and those who receive only standard neonatal intensive care unit (NICU) care.

Secondary aims:

  • To compare length of stay between infants who receive OMM and those who receive only standard NICU care.
  • To compare growth parameters including weight, length, and head circumference, (both means and Z scores) prior to discharge between infants who receive OMM and those who receive only standard NICU care.
  • To compare percentage of subjects requiring nasogastric, orogastric, or gastrostomy tube feeds at discharge between infants who receive OMM and those who receive only standard NICU care.

Study Type

Interventional

Enrollment (Actual)

150

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • New York
      • Rochester, New York, United States, 14642
        • University of Rochester
      • Rochester, New York, United States, 14642
        • Golisano Children's Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 day to 3 months (Child)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • 23 0/7- 33 6/7 weeks' gestational age (GA) at birth, ≥28 0/7 weeks' GA at time of consent
  • stable enough to tolerate gentle manipulation

Exclusion Criteria:

  • > 33 6/7 weeks' GA at birth
  • known congenital and genetic abnormalities affecting neurodevelopment
  • known conditions requiring surgical intervention
  • severe intracranial hemorrhage or other severe neurologic complications
  • parents unable to read and understand English

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: OMM
Neonates randomized to receive osteopathic manipulation
Osteopathic evaluation and treatment (gentle touch according to published protocols) will take about 15 - 20 minutes, and will be performed every 7 - 10 days during the infant's NICU stay once they reach at minimum of at least 28 weeks corrected gestational age and until they reach 36 weeks corrected gestational age.
No Intervention: Control
Neonates randomized to receive standard care only

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Test of Infant Motor Performance (TIMP)
Time Frame: At approximately 36 weeks' corrected gestational age
Standardized, validated assessment of risk for developmental delay; expected range: 20 - 90 with higher scores indicating less risk for developmental delay
At approximately 36 weeks' corrected gestational age

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Length of stay
Time Frame: At NICU discharge, assessed up to 1 year
Number of days in Neonatal Intensive Care Unit (NICU)
At NICU discharge, assessed up to 1 year
Growth parameters - weight
Time Frame: at 36 weeks' corrected gestational age and discharge
weight z-score
at 36 weeks' corrected gestational age and discharge
Growth parameters - length
Time Frame: at 36 weeks' corrected gestational age and discharge
length z-score
at 36 weeks' corrected gestational age and discharge
Growth parameters - head circumference
Time Frame: at 36 weeks' corrected gestational age and discharge
head circumference z-score
at 36 weeks' corrected gestational age and discharge
Need for nasogastric (NG), orogastric (OG), or gastrostomy tube feeds at discharge
Time Frame: at NICU discharge, assessed up to 1 year
Number of neonates requiring NG, OG, or gastrostomy feeds at discharge from NICU
at NICU discharge, assessed up to 1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Ronnie Guillet, MD, PhD, University of Rochester

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 5, 2021

Primary Completion (Actual)

December 1, 2022

Study Completion (Actual)

July 30, 2023

Study Registration Dates

First Submitted

November 25, 2020

First Submitted That Met QC Criteria

December 2, 2020

First Posted (Actual)

December 3, 2020

Study Record Updates

Last Update Posted (Actual)

August 14, 2023

Last Update Submitted That Met QC Criteria

August 11, 2023

Last Verified

August 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

No plans to share HPI and data for individual participants at this time.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Neurodevelopmental Abnormality

Clinical Trials on Osteopathic Manipulative Medicine

3
Subscribe